Pharmigene, Inc. (TPEX:7595)
Taiwan · Delayed Price · Currency is TWD 12.35
+0.15 (1.23%)
Sep 25, 2025, 12:15 PM CST
Pharmigene Revenue
Pharmigene had revenue of 80.68M TWD in the half year ending June 30, 2025, with 50.57% growth. This brings the company's revenue in the last twelve months to 149.25M, up 17.45% year-over-year. In the year 2024, Pharmigene had annual revenue of 116.53M, down -12.19%.
Revenue (ttm)
149.25M
Revenue Growth
+17.45%
P/S Ratio
4.18
Revenue / Employee
n/a
Employees
42
Market Cap
623.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 116.53M | -16.17M | -12.19% |
| Dec 31, 2023 | 132.71M | -1.09M | -0.82% |
| Dec 31, 2022 | 133.80M | 4.45M | 3.44% |
| Dec 31, 2021 | 129.35M | 28.00M | 27.63% |
| Dec 31, 2020 | 101.35M | 36.07M | 55.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caliway Biopharmaceuticals | 44.83M |
| PharmaEssentia | 12.63B |
| Bora Pharmaceuticals Co., LTD. | 21.32B |
| Lotus Pharmaceutical | 19.12B |
| Lumosa Therapeutics | 37.25M |
| Oneness Biotech | 112.57M |
| Polaris Group | 64.02M |
| Center Laboratories | 1.60B |